396,727 Shares of Gossamer Bio, Inc. $GOSS Acquired by Bank of America Corp DE

Key Points

• Bank of America acquired 396,727 shares of Gossamer Bio during the second quarter, valued at approximately $65,000, representing about 0.17% of the company. Institutional investors and hedge funds collectively own 81.23% of Gossamer’s stock.
• Analyst sentiment remains mixed: four analysts rate the stock a Buy, three a Hold, and two a Sell. The consensus rating is Hold, with a target price of $256, while Leerink Partners upgraded the stock to Outperform with an $80 target.
• Gossamer Bio shares opened at $10.78, near the lower end of their 52-week range of $9.10 to $309.60. The clinical-stage biotech is developing seralutinib, an inhaled drug candidate targeting pulmonary vascular remodeling.

Bank of America Corp DE purchased a new position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 396,727 shares of the company's stock, valued at approximately $65,000. Bank of America Corp DE owned approximately 0.17% of Gossamer Bio at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd increased its position in shares of Gossamer Bio by 22.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company's stock valued at $82,000 after purchasing an additional 4,771 shares during the period. Rockefeller Capital Management L.P. boosted its stake in Gossamer Bio by 496.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company's stock valued at $189,000 after buying an additional 50,666 shares in the last quarter. Hsbc Holdings PLC bought a new position in Gossamer Bio during the first quarter valued at about $38,000. SG Americas Securities LLC grew its holdings in Gossamer Bio by 73.4% during the first quarter. SG Americas Securities LLC now owns 128,568 shares of the company's stock worth $42,000 after acquiring an additional 54,439 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new position in Gossamer Bio during the second quarter worth about $35,000. 81.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Leerink Partners upgraded shares of Gossamer Bio from a "market perform" rating to an "outperform" rating and set a $80.00 target price on the stock in a report on Tuesday, July 28th. Weiss Ratings cut shares of Gossamer Bio from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, September 24th. Wall Street Zen lowered shares of Gossamer Bio from a "hold" rating to a "sell" rating in a research report on Sunday, September 20th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Gossamer Bio in a report on Thursday, August 27th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $256.00.

Gossamer Bio Price Performance

Gossamer Bio stock opened at $10.78 on Wednesday. Gossamer Bio, Inc. has a fifty-two week low of $9.10 and a fifty-two week high of $309.60. The firm's 50 day simple moving average is $12.73 and its 200-day simple moving average is $18.00. The company has a market cap of $65.87 million, a P/E ratio of -0.19 and a beta of 2.21.

Gossamer Bio Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations.

Gossamer's lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.